At ObesityWeek taking place in Atlanta, US, Novo Nordisk presented new findings from the STEP UP phase IIIb trial. It showed that, in addition to losing an average… read more.
Each year, about 100,000 Americans experience psychosis, a serious condition that disrupts thoughts and perceptions so profoundly that it can distort a person’s sense of reality. Now—just over… read more.
A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and tirzepatide in patients with type 2 diabetes (T2D). The study found that… read more.
Exicure, Inc, a clinical-stage biotechnology company developing therapeutics for hematologic diseases announced that results from its completed Phase 2 study evaluating burixafor, a small molecule CXCR4 antagonist, will… read more.
Amneal Pharmaceuticals, Inc. announced the U.S. commercial launch of Brekiya (dihydroergotamine mesylate) injection, the first and only ready-to-use dihydroergotamine (DHE) autoinjector approved for the acute treatment of migraine… read more.
People with type 1 diabetes achieved significantly better long-term blood glucose when their levels were monitored by healthcare professionals in real time, via a sensor under the skin,… read more.
Rigel Pharmaceuticals, Inc. a commercial stage biotechnology company focused on hematologic disorders and cancer, announced that data from the ongoing Phase 1b study of R2891, a potent and… read more.
Guardant Health Inc announced new real-world data published in Current Medical Research and Opinion finding that the Shield blood-based screening test demonstrates patient adherence of 95% in screening… read more.
Remote physiologic monitoring (RPM)—digital tools that track patients’ health data between visits—shows promise for improving chronic disease management and reshaping primary care delivery, according to a new study… read more.
Genmab A/S announced that more than 20 abstracts evaluating epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, across lines of therapy and B-cell non-Hodgkin’s lymphoma (NHL) subtypes, will… read more.
Eisai and Merck & Co., Inc., (known as MSD outside of the United States and Canada) announced results from that Phase III LEAP-012 trial evaluating Lenvima (lenvatinib), the… read more.
The rapidly expanding availability of remote telehealth cardiac health care poses a growing challenge for health care providers to learn how to use new digital tools and resources… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
